Ravelcare schedules AGM for September 23 to approve director reappointments
- Ravelcare schedules 8th AGM for September 23, 2026, via Video Conferencing
- Agenda includes reappointment of MD Ayush Varma and WTD Maheshkumar Varma
- FY26 revenue rose 7.9% to ₹2,695.43 lakhs; PAT increased 1.3% to ₹515.40 lakhs
- Company remains debt-free with net worth of ₹3,740.84 lakhs
- No dividend proposed for FY26; funds preserved for manufacturing integration

*this image is generated using AI for illustrative purposes only.
Ravelcare has scheduled its 8th Annual General Meeting (AGM) for Wednesday, September 23, 2026, at 11:30 am via Video Conferencing. The meeting agenda includes the reappointment of key directors and the adoption of audited financial statements for FY26.
Corporate Governance Updates
Shareholders will vote on the reappointment of Mr. Ayush Varma as Managing Director for a further period of three years, effective June 20, 2027. His remuneration is capped at ₹75 lakhs per annum. The Board also seeks approval for the reappointment of Mr. Maheshkumar Varma as Whole-time Director for three years, with remuneration up to ₹30 lakhs per annum.
Additionally, Mrs. Anita Mahesh Varma retires by rotation and offers herself for reappointment as Non-Executive Director. The cut-off date for determining shareholder eligibility for voting is September 16, 2026. Remote e-voting will commence on September 20, 2026, at 9:00 am and end on September 22, 2026, at 5:00 pm.
FY26 Financial Performance
For the fiscal year ended March 31, 2026, Ravelcare reported revenue from operations of ₹2,695.43 lakhs, a 7.9% increase over the previous year. Profit after tax stood at ₹515.40 lakhs, representing a net profit margin of 19.1%. The company remains debt-free with a net worth of ₹3,740.84 lakhs.
| Metric | FY26 Value | YoY Change |
|---|---|---|
| Revenue | ₹2,695.43 lakhs | +7.9% |
| Profit After Tax | ₹515.40 lakhs | +1.3% |
| Net Worth | ₹3,740.84 lakhs | N/A |
Other income declined to ₹8.29 lakhs from ₹31.91 lakhs in the prior year. Total expenses rose to ₹1,996.47 lakhs from ₹1,826.44 lakhs. The Board did not propose any dividend for FY26, opting to preserve resources for growth initiatives.
Product Expansion and Strategy
The company launched Ravel PRO, a clinical haircare line, in June 2026. This range targets specific concerns such as hair fall and dandruff and is available across major e-commerce and quick-commerce platforms. Two additional PRO products are scheduled for launch in September 2026.
Management plans to launch an AI-led diagnostic skincare range in the second half of FY27. Funds from the December 2025 IPO, which raised ₹2,410.20 lakhs, remain largely unutilised and are held in bank fixed deposits. These funds are earmarked for backward integration into manufacturing and general corporate purposes.
Historical Stock Returns for Ravelcare
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| 0.0% | 0.0% | -9.80% | -30.83% | -47.47% | -47.47% |
How will the upcoming launch of the AI-led diagnostic skincare range in H2 FY27 impact Ravelcare's revenue diversification and competitive positioning against established dermatological brands?
Given that IPO proceeds are currently held in fixed deposits, what is the specific timeline and strategic roadmap for deploying these funds into backward integration and manufacturing capabilities?
With net profit growth lagging behind revenue growth in FY26, what operational efficiencies or cost-control measures are management planning to implement to improve margins in the coming fiscal year?





























